MA41097A - Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses - Google Patents

Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses

Info

Publication number
MA41097A
MA41097A MA041097A MA41097A MA41097A MA 41097 A MA41097 A MA 41097A MA 041097 A MA041097 A MA 041097A MA 41097 A MA41097 A MA 41097A MA 41097 A MA41097 A MA 41097A
Authority
MA
Morocco
Prior art keywords
antibodies
inhibitoral
derivatives
enhanced
properties
Prior art date
Application number
MA041097A
Other languages
English (en)
Inventor
Sachin Kumar Dubey
Adrian Walmsley
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/562,297 external-priority patent/US20150183885A1/en
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MA41097A publication Critical patent/MA41097A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
MA041097A 2014-12-05 2015-12-06 Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses MA41097A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/562,297 US20150183885A1 (en) 2012-06-08 2014-12-05 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP15165107 2015-04-24

Publications (1)

Publication Number Publication Date
MA41097A true MA41097A (fr) 2017-10-10

Family

ID=54838344

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041097A MA41097A (fr) 2014-12-05 2015-12-06 Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses

Country Status (7)

Country Link
EP (1) EP3227334A1 (fr)
JP (1) JP2018505853A (fr)
CN (1) CN107207599A (fr)
CA (1) CA2969940A1 (fr)
HK (1) HK1244012A1 (fr)
MA (1) MA41097A (fr)
WO (1) WO2016087677A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
CA3081094A1 (fr) * 2017-11-20 2019-05-23 Alison J. GILLESPIE Formulations d'aflibercept contenant un sel de lysine en tant qu'agent de tonicification et leurs utilisations
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
US20220204630A1 (en) * 2019-05-30 2022-06-30 Sunshine Lake Pharma Co., Ltd. Anti-trka antibodies and uses thereof
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
WO2023125490A1 (fr) * 2021-12-28 2023-07-06 4B Technologies (Suzhou) Limited Anticorps anti-trka et application de celui-ci

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101414438B1 (ko) * 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
NZ587701A (en) * 2008-02-04 2013-03-28 Lay Line Genomics Spa Anti-trka antibodies and derivatives thereof
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2859019B1 (fr) * 2012-06-08 2018-02-21 Glenmark Pharmaceuticals S.A. Anticorps humanisés anti-trka avec substitutions d'acides aminés

Also Published As

Publication number Publication date
WO2016087677A1 (fr) 2016-06-09
JP2018505853A (ja) 2018-03-01
EP3227334A1 (fr) 2017-10-11
CN107207599A (zh) 2017-09-26
CA2969940A1 (fr) 2016-06-09
HK1244012A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
HK1259075A1 (zh) Bcma抗體和其用以治療癌症和免疫病症的用途
MA44146A (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
MA41097A (fr) Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
IL286888A (en) Use of pyridofidine to treat depression and anxiety
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
IL304429A (en) Methods and preparations for the treatment of epileptic disorders
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
IL252943A0 (en) Sunitinib formulations and methods of using them for the treatment of eye diseases
EA201691582A1 (ru) Новые фармацевтические препараты
MA44391A (fr) Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
MA43378A (fr) Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
HK1249016A1 (zh) 使用抗il-34抗體治療神經疾病的組合物和方法
MA43361A (fr) Composition pour le soin et la protection de cultures
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
IL264070A (en) Methods and preparations for the treatment of disorders and diseases involving rdh12
IL254386A0 (en) NK-3 receptor antagonists for medical or cosmetic treatment of excess body fat
EP3534932A4 (fr) Traitement de maladies associées à l'igfb3 et à son récepteur
MA50532A (fr) Compositions et méthodes pour le traitement de cancers
MA40868A (fr) Combinaisons pharmaceutiques de sitagliptine et d'agonistes de ppar
FR3031902B1 (fr) Composition de complement alimentaire apres intervention medicale pour traiter l’obesite
MA44978A (fr) Combinaison d'anticorps anti-pd-1 et de rayonnement pour traiter le cancer